protein

Recombinant Human beta-Defensin 2 (rHu BD-2)

MBS546026

0.005 mg

165 USD

Protein

Recombinant Human beta-Defensin 2 (rHu BD-2)

[beta-Defensin 2]

[beta-Defensin 2; human BD-2; Human beta-Defensin 2]

[beta-defensin 2; Beta-defensin 4A; beta-defensin 4A; defensin, beta 2; defensin, beta 4; skin-antimicrobial peptide 1; defensin, beta 4A; Beta-defensin 2; BD-2; hBD-2; Defensin, beta 2; Skin-antimicrobial peptide 1]

[DEFB4A; DEFB4A; BD-2; SAP1; DEFB2; DEFB4; HBD-2; DEFB-2; DEFB102; DEFB102; DEFB2; DEFB4; BD-2; hBD-2; SAP1]

DFB4A_HUMAN

Escherichia coli

64

GIGDPVTCLK SGAICHPVFC PRRYKQIGTC GLPGTKCCKK P

>98% by SDS-PAGE and HPLC analyses

Lyophilized from a 0.2 um filtered concentrated (1.0mg/ml) solution in 20mM PB, pH 7.4, 130mM NaCl.

This lyophilized preparation is stable at 2-8°C, but should be kept at -20°C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -70°C. Avoid repeated freeze/thaw cycles.

Biological Activity: Fully biologically active when compared to standard. Determined by its ability to chemoattract immature human dendritic cells using a concentration range of 10-100 ng/ml. Physical Appearance: Sterile Filtered White lyophilized (freeze-dried) powder. Endotoxin: Less than 1EU/ug of rHuBD-2 as determined by LAL method.

Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at -20°C. Further dilutions should be made in appropriate buffered solutions.

Defensins (alpha and beta) are cationic peptides with a broad spectrum of antimicrobial activity that comprise an important arm of the innate immune system. The alpha-defensins are distinguished from the beta-defensins by the pairing of their three disulfide bonds. To date, four human beta-defensins have been identified; BD-1, BD-2, BD-3 and BD-4. beta-defensins are expressed on some leukocytes and at epithelial surfaces. In addition to their direct antimicrobial activities, they are chemoattractant towards immature dendritic cells and memory T cells. The beta- defensin proteins are expressed as the C-terminal portion of precursors and are released by proteolytic cleavage of a signal sequence and, in the case of BD-1 (36 a.a.), a propeptide region. beta-defensins contain a six-cysteine motif that forms three intra-molecular disulfide bonds. beta-Defensins are 3-5 kDa peptides ranging in size from 33-47 amino acid residues.

3510600

AAC33549.1

O15263

Approximately 4.3 KDa, a single non-glycosylated polypeptide chain containing 41 amino acids.

Beta Defensins Pathway (530759); Defensins Pathway (530757); Immune System Pathway (106386); Innate Immune System Pathway (106387)

Defensins form a family of microbicidal and cytotoxic peptides made by neutrophils. Members of the defensin family are highly similar in protein sequence. This gene encodes defensin, beta 4, an antibiotic peptide which is locally regulated by inflammation. [provided by RefSeq, Jul 2008]

defensin, beta 2: Has antibacterial activity (Potential). Belongs to the beta-defensin family. LAP/TAP subfamily. Protein type: Motility/polarity/chemotaxis; Secreted; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 8p23.1. Cellular Component: Golgi lumen; extracellular region. Biological Process: G-protein coupled receptor protein signaling pathway; defense response to bacterium; innate immune response; immune response; chemotaxis

0.005 mg

165 USD

0.02 mg

220

1 mg

2050